Edward Pan

List of Publications by Year
in descending order

44 papers	864 citations	567281 15 h-index	501196 28 g-index
45 all docs	45 docs citations	45 times ranked	1590 citing authors

#	Article	IF	Citations
1	A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clinical Cancer Research, 2019, 25, 5799-5807.	7.0	166
2	A TNFâ€"JNKâ€"Axlâ€"ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma. Nature Neuroscience, 2017, 20, 1074-1084.	14.8	82
3	Interleukin-13 receptor alpha 2 cooperates with EGFRvIII signaling to promote glioblastoma multiforme. Nature Communications, 2017, 8, 1913.	12.8	62
4	Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 302-311.	1.7	60
5	Reversibly Modulating the Bloodâ€"Brain Barrier by Laser Stimulation of Molecular-Targeted Nanoparticles. Nano Letters, 2021, 21, 9805-9815.	9.1	49
6	In vivo detection of 2â€hydroxyglutarate in brain tumors by optimized pointâ€resolved spectroscopy (PRESS) at 7T. Magnetic Resonance in Medicine, 2017, 77, 936-944.	3.0	40
7	Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of Neuro-Oncology, 2016, 130, 571-579.	2.9	39
8	Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. Neuro-Oncology, 2020, 22, 1018-1029.	1.2	37
9	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. Journal of Neuro-Oncology, 2017, 133, 183-192.	2.9	30
10	Echoâ€planar spectroscopic imaging with dualâ€readout alternated gradients (DRAGâ€EPSI) at 7 T: Application for 2â€hydroxyglutarate imaging in glioma patients. Magnetic Resonance in Medicine, 2018, 79, 1851-1861.	3.0	30
11	Seizures in glioma patients: An overview of incidence, etiology, and therapies. Journal of the Neurological Sciences, 2019, 404, 80-85.	0.6	30
12	Detection of 2â€hydroxyglutarate in brain tumors by tripleâ€refocusing MR spectroscopy at 3T in vivo. Magnetic Resonance in Medicine, 2017, 78, 40-48.	3.0	28
13	Basis for Immunotherapy for Treatment of Meningiomas. Frontiers in Neurology, 2020, 11, 945.	2.4	27
14	NRG/RTOG 1122: A phase 2, doubleâ€blinded, placeboâ€controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer, 2020, 126, 2821-2828.	4.1	25
15	Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients. Clinical and Experimental Metastasis, 2020, 37, 531-539.	3.3	16
16	PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 159-162.	1.3	15
17	Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression. Journal of Neuro-Oncology, 2018, 139, 731-738.	2.9	12
18	Retrospective study of patients with brain metastases from melanoma receiving concurrent whole-brain radiation and temozolomide. Anticancer Research, 2011, 31, 4537-43.	1.1	12

#	Article	IF	Citations
19	In vivo MRS measurement of 2â€hydroxyglutarate in patientâ€derived IDHâ€mutant xenograft mouse models versus glioma patients. Magnetic Resonance in Medicine, 2020, 84, 1152-1160.	3.0	11
20	A Modified Nucleoside 6-Thio-2â€²-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	7.0	10
21	Measurement of glycine in healthy and tumorous brain by tripleâ€refocusing MRS at 3ÂT in vivo. NMR in Biomedicine, 2017, 30, e3747.	2.8	9
22	3D highâ€resolution imaging of 2â€hydroxyglutarate in glioma patients using DRAGâ€EPSI at 3T in vivo. Magnetic Resonance in Medicine, 2019, 81, 795-802.	3.0	9
23	Brainstem Glioblastoma Multiforme in a Patient with NF1. Anticancer Research, 2018, 38, 4897-4900.	1.1	8
24	Spinal Pleomorphic Xanthoastrocytoma With aQKI-RAF1Fusion. Journal of Neuropathology and Experimental Neurology, 2019, 78, 10-14.	1.7	8
25	Spectral fitting strategy to overcome the overlap between 2â€hydroxyglutarate and lipid resonances at 2.25 ppm. Magnetic Resonance in Medicine, 2021, 86, 1818-1828.	3.0	7
26	Adult Primary Peripheral PNET/Ewing's Sarcoma of the Cervical and Thoracic Spine. Anticancer Research, 2019, 39, 4463-4465.	1.1	6
27	H3 K27M Mutations in Thalamic Pilocytic Astrocytomas with Anaplasia. World Neurosurgery, 2019, 124, 87-92.	1.3	6
28	Occurrence of Glioma in Pregnant Patients: An Institutional Case Series and Review of the Literature. Anticancer Research, 2020, 40, 3453-3457.	1.1	6
29	Spinal Cord Pilocytic Astrocytoma With FGFR1-TACC1 Fusion and Anaplastic Transformation. Journal of Neuropathology and Experimental Neurology, 2021, 80, 283-285.	1.7	6
30	An Adult Patient With Rare Primary Intracranial Alveolar Rhabdomyosarcoma. Anticancer Research, 2019, 39, 3067-3070.	1.1	4
31	Primary central nervous system sarcomas in adults: A systematic review. Clinical Neurology and Neurosurgery, 2022, 214, 107127.	1.4	4
32	Review of rituximab in primary CNS lymphoma. Journal of the Neurological Sciences, 2020, 410, 116649.	0.6	3
33	Phase I study of bendamustine with concurrent whole brain radiation therapy in patients with brain metastases from solid tumors. Journal of Neuro-Oncology, 2014, 119, 413-420.	2.9	2
34	Post-Traumatic Gliomas in Adults: Review of the Case Reports and Studies. Canadian Journal of Neurological Sciences, 2022, , 1-8.	0.5	2
35	NCMP-07. SECONDARY ADRENAL INSUFFICIENCY IN ADULT PATIENTS WITH GLIOMA: A CASE SERIES. Neuro-Oncology, 2019, 21, vi180-vi180.	1.2	1
36	Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response. Blood, 2020, 136, 12-12.	1.4	1

#	Article	IF	Citations
37	PATH-59. THALAMIC GLIOMAS WITH H3 K27M MUTATION. A CASE SERIES AND LITERATURE REVIEW. Neuro-Oncology, 2018, 20, vi171-vi171.	1.2	0
38	HOUT-06. PATTERN OF LOW FIELD INTENSITY RECURRENCE IN HIGH-GRADE GLIOMAS FOLLOWING TUMOR TREATMENT FIELD THERAPY. Neuro-Oncology, 2018, 20, vi114-vi114.	1.2	0
39	RARE-37. OCCURRENCE OF GLIOMA IN PREGNANT PATIENTS: INSTITUTIONAL CASE SERIES AND REVIEW OF THE LITERATURE. Neuro-Oncology, 2018, 20, vi243-vi243.	1.2	0
40	NIMG-76. POST-GADOLINIUM 3-DIMENSIONAL SPATIAL, SURFACE, AND STRUCTURAL CHARACTERISTICS OF GLIOBLASTOMAS DIFFERENTIATE PSEUDOPROGRESSION FROM TRUE TUMOR PROGRESSION. Neuro-Oncology, 2018, 20, vi192-vi193.	1.2	0
41	NIMG-13. GLYCINE IS A METABOLIC BIOMARKER OF MALIGNANCY IN GLIOMAS: IN VIVO MAGNETIC RESONANCE SPECTROSCOPY STUDY. Neuro-Oncology, 2019, 21, vi164-vi164.	1.2	0
42	NIMG-08. 2-HYDROXYGLUTARATE MAGNETIC RESONANCE SPECTROSCOPY IN BRAINSTEM TUMOR PATIENTS IN VIVO. Neuro-Oncology, 2019, 21, vi163-vi163.	1.2	0
43	BIMG-09. GLUTAMINE AND GLYCINE BY MR SPECTROSCOPY IDENTIFY AGGRESSIVE GLIOMAS. Neuro-Oncology Advances, 2021, 3, i2-i3.	0.7	0
44	NIMG-24. GLYCINE AND GLUTAMINE BY MR SPECTROSCOPY ARE IMAGING BIOMARKERS OF GLIOMA AGGRESSIVENESS. Neuro-Oncology, 2020, 22, ii152-ii152.	1.2	0